\n\nBiologic medicines are made from living cells and are among the most expensive therapies available. While they account for only 5% of all prescriptions, they are responsible for a staggering 51% of total drug spending in the United States. To address this imbalance, the FDA is prioritising the expansion of the biosimilar market.\n\n\n\nThe new FDA biosimilar development guidance focuses on…